

Pregnancy Planning Should Include Flu Shots

BY HEIDI SPLETE

Women seeking fertility treatments—and all women planning a pregnancy—should be vaccinated against both the seasonal flu and pandemic influenza A(H1N1), according to a joint statement from the Centers for Disease Control and Prevention and the American Society for Reproductive Medicine.

“Fertility clinics should encourage patients planning pregnancy to be vaccinated for both seasonal influenza and 2009 H1N1,” the statement noted. Since certain areas of the United States may have the H1N1 vaccine available only for those in initial target groups—including women who are already pregnant or those who are caring for infants younger than age 6 months—some who are planning a pregnancy may have to wait until

more H1N1 vaccine is available. Women planning a pregnancy can receive the seasonal flu shot at any time.

Women who are pregnant should receive the inactivated injectable vaccine for both the H1N1 and seasonal flu vaccines (not the live, activated nasal spray vaccine). Women who are planning a pregnancy and have no medical contraindications for the live, activated vaccine can receive either the injection or

the nasal spray for both vaccines before conceiving, according to the statement.

Data have shown that pregnant women infected with the pandemic H1N1 virus have higher rates of hospitalization and death from flu-related complications, compared with the general population.

Visit cdc.gov/h1n1flu or flu.gov for the latest H1N1 and seasonal flu vaccine information. ■

Pap Smear Rivals Liquid Cytology On Sensitivity

Automated, liquid-based cytology was found to be no more sensitive or specific than standard Pap smears in detecting cervical intraepithelial neoplasia or cancer, according to a report.

In what they described as “the largest high-quality study performed in a population-based setting with blind verification of follow-up outcomes of all test-positive cases,” the study’s investigators found that liquid-based cytology was not superior to Pap testing.

Until now, neither screening method has been definitively established as better than the other, because there haven’t been enough well-designed comparative studies, wrote Dr. Albertus G. Siebers of Radboud University Nijmegen (the Netherlands) Medical Center and associates.

Nevertheless, liquid-based cytology has virtually replaced conventional Pap smears in the United States. It is preferred by most laboratories, because specimens are more easily and rapidly scanned under the microscope, Dr. Mark Schiffman and Dr. Diane Solomon wrote in an editorial (*JAMA* 2009;302:1809-10).

The investigators assessed testing outcomes in 84,322 Dutch women aged 30-60 years who were screened at 246 family practices. A total of 45,818 women attended practices that had been randomly assigned to use liquid-based cytology and 38,504 attended practices that had been assigned to use Pap smears.

In an intention-to-treat analysis, the adjusted detection rate ratios for cervical intraepithelial neoplasia (CIN) grade 1+ was 1.01; for CIN grade 2+ was 1.00; for CIN grade 3+ was 1.05, and for carcinoma was 1.69.

“Our study found no difference in sensitivity in terms of histological detection rates of cervical lesions, or in the positive predictive values between liquid-based cytology and Pap test, indicating that the accuracy of both methods is comparable,” the investigators reported (*JAMA* 2009;302:1757-64).

Mr. Siebers reported no conflicts of interest. Dr. Schiffman and Dr. Solomon reported that they are serving as medical monitors of the Costa Rican HPV Vaccine Trial, which is supported in part by GSK Biologicals and GlaxoSmithKline.

—Mary Ann Moon



Indications and usage

Levemir® is indicated for once- or twice-daily subcutaneous administration for the treatment of adult and pediatric patients with type 1 diabetes mellitus or adult patients with type 2 diabetes mellitus who require basal (long-acting) insulin for the control of hyperglycemia.

Important safety information

Levemir® is contraindicated in patients hypersensitive to insulin detemir or one of its excipients.

Hypoglycemia is the most common adverse effect of all insulin therapies, including Levemir®. As with other insulins, the timing of hypoglycemic events may differ among various insulin preparations. Glucose monitoring is recommended for all patients with diabetes. Levemir® is not to be used in insulin infusion pumps. Any change of insulin dose should be made cautiously and only under medical supervision. Concomitant oral antidiabetes treatment may require adjustment.

Inadequate dosing or discontinuation of treatment may lead to hyperglycemia and, in patients with type 1 diabetes, diabetic ketoacidosis. Levemir® should not be diluted or mixed with any

other insulin preparations. Insulin may cause sodium retention and edema, particularly if previously poor metabolic control is improved by intensified insulin therapy. Dose and timing of administration may need to be adjusted to reduce the risk of hypoglycemia in patients being switched to Levemir® from other intermediate or long-acting insulin preparations. The dose of Levemir® may need to be adjusted in patients with renal or hepatic impairment.

Other adverse events commonly associated with insulin therapy may include injection site reactions (on average, 3% to 4% of patients in clinical trials) such as lipodystrophy, redness, pain, itching, hives, swelling, and inflammation.

*Whether these observed differences represent true differences in the effects of Levemir®, NPH insulin, and insulin glargine is not known, since these trials were not blinded and the protocols (eg, diet and exercise instructions and monitoring) were not specifically directed at exploring hypotheses related to weight effects of the treatments compared. The clinical significance of the observed differences in weight has not been established.

For your patients with type 2 diabetes, start once-daily Levemir®

Levemir® helps patients with diabetes achieve their A1C goal.^{2,3}

- 24-hour action at a once-daily dose^{4,5}
- Provides consistent insulin absorption and action, day after day^{4,6,7}
- Less weight gain^{8*}

To access complimentary e-learning programs, visit novomedlink.com/Levemir

References: 1. Data on file. Novo Nordisk Inc, Princeton, NJ. 2. Meneghini LF, Rosenberg KH, Koenen C, Meriläinen MJ, Lüdtke H-J. Insulin detemir improves glycaemic control with less hypoglycaemia and no weight gain in patients with type 2 diabetes who were insulin naive or treated with NPH or insulin glargine: clinical practice experience from a German subgroup of the PREDICTIVE study. *Diabetes Obes Metab*. 2007;9(3):418-427. 3. Hermansen K, Davies M, Derezinski T, Ravn GM, Clauson P, Home P, for the Levemir Treat-to-Target Study Group. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naïve people with type 2 diabetes. *Diabetes Care*. 2006;29(6):1269-1274. 4. Klein O, Lyngø J, Endahl L, Damholt B, Nosek L, Heise T. Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetes. *Diabetes Obes Metab*. 2007;9(3):290-299. 5. Philis-Tsimikas A, Charpentier G, Clauson P, Ravn GM, Roberts VL, Thorsteinsson B. Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes. *Clin Ther*. 2006;28(10):1569-1581. 6. Danne T, Endahl L, Haahr H, et al. Lower within-subject variability in pharmacokinetic profiles of insulin detemir in comparison to insulin glargine in children and adolescents with type 1 diabetes. Presented at: 43rd Annual Meeting of the European Association for the Study of Diabetes; September 17-21, 2007; Amsterdam, Netherlands. Abstract 0189. 7. Heise T, Nosek L, Rønn BB, et al. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. *Diabetes*. 2004;53(6):1614-1620. 8. Data on file. NDA21-536. Novo Nordisk Inc, Princeton, NJ.



Please see brief summary of Prescribing Information on adjacent page.

FlexPen® and Levemir® are registered trademarks of Novo Nordisk A/S.
© 2008 Novo Nordisk Inc. 133236-R2 November 2008

